Medical device company Atomo Diagnostics (ASX: AT1) has locked in purchase orders from Viatris Healthcare Pty Ltd amounting to approximately $970,000 for HIV Self-Tests. These tests, manufactured by Atomo under the Mylan brand, are designated for supply to several Low- and Middle-Income Countries (LMICs). The orders are scheduled for production during the second half of
Read More
Ranked fourth among countries with the highest HIV prevalence in the world, there were about 7.5 million people living with HIV in South Africa in 2021, and the number keeps growing. Subsequently, the HIV test market in South Africa is also growing as HIV testing initiatives have been implemented to increase access to testing and
Read More
Three companies are joining forces to help tackle one of the most serious public health challenges of our time – the HIV/AIDS epidemic. Viatris and Atomo Diagnostics (ASX: AT1) have announced an agreement with Unitaid to increase accessibility of HIV self-testing in low-and middle-income countries (LMICs). The announcement represents significant market expansion, with Unitaid committing
Read More